Clinical Trials Browser

Phase 1 × Graft vs Host Disease × 1 year × Clear all

Graft vs Host Disease, Myelodysplastic Syndromes

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT04678401 2025-10-20

IS-free Treg HaploHCT

Phase 1 Recruiting

30 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04473911 2025-07-20

Haplo Peripheral Blood Sct In GVHD Prevention

Phase 1 Completed

25 enrolled

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

15 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06462365 2025-04-15

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Phase 1 Recruiting

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

IS-free Treg HaploHCT

Haplo Peripheral Blood Sct In GVHD Prevention

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)